Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Ischemic Heart Disease

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 102 articles:
HTML format
Text format



Single Articles


    March 2018
  1. ALKHALIL M
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:936.
    PubMed     Text format    


  2. KANDZARI DE, Mauri L, Koolen JJ, Doros G, et al
    Bioresorbable polymer drug-eluting stents - Authors' reply.
    Lancet. 2018;391:936-937.
    PubMed     Text format    


  3. SHAH R
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:935-936.
    PubMed     Text format    


  4. MOTOVSKA Z, Bhatt DL
    12 months of DAPT after acute coronary syndrome still beats 6 months.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30612.
    PubMed     Text format    


  5. HAHN JY, Song YB, Oh JH, Cho DK, et al
    6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30493.
    PubMed     Text format     Abstract available


    February 2018
  6. HEAD SJ, Milojevic M, Daemen J, Ahn JM, et al
    Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30423.
    PubMed     Text format     Abstract available


  7. PAULES CI, Subbarao K
    Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
    Lancet. 2018;391:427-428.
    PubMed     Text format    


  8. CALDEIRA D, Ferreira JJ, Costa J
    Influenza vaccination and prevention of cardiovascular disease mortality.
    Lancet. 2018;391:426-427.
    PubMed     Text format    


    January 2018
  9. JOBS A, Desch S, Thiele H
    Great expectations - Authors' reply.
    Lancet. 2018;391:306-307.
    PubMed     Text format    


  10. LEMESLE G, Laine M, Pankert M, Puymirat E, et al
    Great expectations.
    Lancet. 2018;391:306.
    PubMed     Text format    


  11. BOCHATON T, Ovize M
    Circadian rhythm and ischaemia-reperfusion injury.
    Lancet. 2018;391:8-9.
    PubMed     Text format    


  12. BROWN DL, Redberg RF
    Last nail in the coffin for PCI in stable angina?
    Lancet. 2018;391:3-4.
    PubMed     Text format    


  13. GERBER RT, Gershlick AH
    A SENIOR moment? Bare-metal stents in elderly patients.
    Lancet. 2018;391:4-6.
    PubMed     Text format    


    December 2017
  14. SCHUMACHER H, Mahfoud F, Bohm M
    Overestimation of cardiovascular outcome incidence - Authors' reply.
    Lancet. 2017;390:2547.
    PubMed     Text format    


  15. YE Y, Fonseca R
    Overestimation of cardiovascular outcome incidence.
    Lancet. 2017;390:2546-2547.
    PubMed     Text format    


  16. THURSTON GD, Newman JD
    Walking to a pathway for cardiovascular effects of air pollution.
    Lancet. 2017 Dec 5. pii: S0140-6736(17)33078.
    PubMed     Text format    


  17. SINHARAY R, Gong J, Barratt B, Ohman-Strickland P, et al
    Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cr
    Lancet. 2017 Dec 5. pii: S0140-6736(17)32643.
    PubMed     Text format     Abstract available


  18. DE WINTER RJ, Katagiri Y, Asano T, Milewski KP, et al
    A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 tri
    Lancet. 2017 Dec 1. pii: S0140-6736(17)33103.
    PubMed     Text format     Abstract available


    November 2017
  19. RIDKER PM, MacFadyen JG, Everett BM, Libby P, et al
    Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Lancet. 2017 Nov 13. pii: S0140-6736(17)32814.
    PubMed     Text format     Abstract available


  20. CONNOLLY SJ, Eikelboom JW, Bosch J, Dagenais G, et al
    Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Nov 10. pii: S0140-6736(17)32458.
    PubMed     Text format     Abstract available


  21. PRABHAKARAN D, Anand S, Watkins D, Gaziano T, et al
    Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.
    Lancet. 2017 Nov 3. pii: S0140-6736(17)32471.
    PubMed     Text format     Abstract available


  22. AL-LAMEE R, Thompson D, Dehbi HM, Sen S, et al
    Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
    Lancet. 2017 Nov 1. pii: S0140-6736(17)32714.
    PubMed     Text format     Abstract available


    October 2017
  23. VARENNE O, Cook S, Sideris G, Kedev S, et al
    Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.
    Lancet. 2017 Oct 31. pii: S0140-6736(17)32713.
    PubMed     Text format     Abstract available


  24. MONTAIGNE D, Marechal X, Modine T, Coisne A, et al
    Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbalpha antagonism: a single-centre propensity-matched cohort study and a randomised study.
    Lancet. 2017 Oct 26. pii: S0140-6736(17)32132.
    PubMed     Text format     Abstract available


  25. BYRNE RA, Schuster T
    Biodegradable polymer drug-eluting stents: caveat emptor.
    Lancet. 2017;390:1814-1816.
    PubMed     Text format    


    September 2017
  26. LEAR SA, Hu W, Rangarajan S, Gasevic D, et al
    The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study.
    Lancet. 2017 Sep 21. pii: S0140-6736(17)31634.
    PubMed     Text format     Abstract available


    August 2017
  27. DEHGHAN M, Mente A, Zhang X, Swaminathan S, et al
    Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study.
    Lancet. 2017 Aug 28. pii: S0140-6736(17)32252.
    PubMed     Text format     Abstract available


  28. MILLER V, Mente A, Dehghan M, Rangarajan S, et al
    Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study.
    Lancet. 2017 Aug 28. pii: S0140-6736(17)32253.
    PubMed     Text format     Abstract available


  29. SIBBING D, Aradi D, Jacobshagen C, Gross L, et al
    Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32155.
    PubMed     Text format     Abstract available


  30. KANDZARI DE, Mauri L, Koolen JJ, Massaro JM, et al
    Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32249.
    PubMed     Text format     Abstract available


  31. JINATONGTHAI P, Kongwatcharapong J, Foo CY, Phrommintikul A, et al
    Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis.
    Lancet. 2017;390:747-759.
    PubMed     Text format     Abstract available


  32. CUISSET T, Verheugt FWA, Mauri L
    Update on antithrombotic therapy after percutaneous coronary revascularisation.
    Lancet. 2017;390:810-820.
    PubMed     Text format     Abstract available


  33. MINTZ GS, Guagliumi G
    Intravascular imaging in coronary artery disease.
    Lancet. 2017;390:793-809.
    PubMed     Text format     Abstract available


  34. THE LANCET
    40 years of percutaneous coronary intervention: where next?
    Lancet. 2017;390:715.
    PubMed     Text format    


  35. DAMMAN P, de Winter RJ
    Timing of revascularisation for acute coronary syndrome.
    Lancet. 2017 Aug 1. pii: S0140-6736(17)31632.
    PubMed     Text format    


  36. JOBS A, Mehta SR, Montalescot G, Vicaut E, et al
    Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials.
    Lancet. 2017 Aug 1. pii: S0140-6736(17)31490.
    PubMed     Text format     Abstract available


    July 2017
  37. ALI ZA, Serruys PW, Kimura T, Gao R, et al
    2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
    Lancet. 2017 Jul 18. pii: S0140-6736(17)31470.
    PubMed     Text format     Abstract available


    May 2017
  38. RUTTY GN, Morgan B, Robinson C, Raj V, et al
    Diagnostic accuracy of post-mortem CT with targeted coronary angiography versus autopsy for coroner-requested post-mortem investigations: a prospective, masked, comparison study.
    Lancet. 2017 May 24. pii: S0140-6736(17)30333.
    PubMed     Text format     Abstract available


    April 2017
  39. KOOPMAN JJE, Kuipers RS
    From arterial ageing to cardiovascular disease.
    Lancet. 2017;389:1676-1678.
    PubMed     Text format    


  40. KAHAN T
    Target blood pressure in patients at high cardiovascular risk.
    Lancet. 2017 Apr 5. pii: S0140-6736(17)30935.
    PubMed     Text format    


  41. BOHM M, Schumacher H, Teo KK, Lonn EM, et al
    Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Lancet. 2017 Apr 5. pii: S0140-6736(17)30754.
    PubMed     Text format     Abstract available


  42. VIDAL-PETIOT E, Bhatt DL, Fox KM, Steg PG, et al
    Blood pressure and cardiovascular outcomes: a closer look - Authors' reply.
    Lancet. 2017;389:1296-1297.
    PubMed     Text format    


  43. WALD NJ, Wald DS
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1296.
    PubMed     Text format    


  44. DOUMAS M, Stavropoulos KV, Boutari C, Imprialos KP, et al
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1295-1296.
    PubMed     Text format    


    March 2017
  45. SCHOOLING CM
    Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease?
    Lancet. 2017 Mar 27. pii: S0140-6736(16)31648.
    PubMed     Text format     Abstract available


  46. GURBEL PA, Tantry US
    GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes.
    Lancet. 2017 Mar 17. pii: S0140-6736(17)30760.
    PubMed     Text format    


  47. OHMAN EM, Roe MT, Steg PG, James SK, et al
    Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Lancet. 2017 Mar 17. pii: S0140-6736(17)30751.
    PubMed     Text format     Abstract available


  48. KAPLAN H, Thompson RC, Trumble BC, Wann LS, et al
    Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study.
    Lancet. 2017 Mar 16. pii: S0140-6736(17)30752.
    PubMed     Text format     Abstract available


  49. THE LANCET
    Polypills: an essential medicine for cardiovascular disease.
    Lancet. 2017;389:984.
    PubMed     Text format    


  50. HUFFMAN MD, Xavier D, Perel P
    Uses of polypills for cardiovascular disease and evidence to date.
    Lancet. 2017;389:1055-1065.
    PubMed     Text format     Abstract available


    January 2017
  51. BLACHER J, Levy BI, Mourad JJ, Safar ME, et al
    Hypertension control and cardiovascular disease - Authors' reply.
    Lancet. 2017;389:154-155.
    PubMed     Text format    


  52. JAMES JE
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:154.
    PubMed     Text format    


  53. MESSERLI FH, Fischer U, Rimoldi SF, Bangalore S, et al
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:153.
    PubMed     Text format    


  54. TAWAKOL A, Ishai A, Takx RA, Figueroa AL, et al
    Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study.
    Lancet. 2017 Jan 12. pii: S0140-6736(16)31714.
    PubMed     Text format     Abstract available


    November 2016
  55. COLLINS R, Reith C, Emberson J, Armitage J, et al
    Interpretation of the evidence for the efficacy and safety of statin therapy.
    Lancet. 2016;388:2532-2561.
    PubMed     Text format     Abstract available


    October 2016
  56. MAKIKALLIO T, Holm NR, Lindsay M, Spence MS, et al
    Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32052.
    PubMed     Text format     Abstract available


  57. MACK M, Holmes DR
    Randomised trials in left main disease: a NOBLE effort.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32067.
    PubMed     Text format    


  58. VON BIRGELEN C, Kok MM, van der Heijden LC, Danse PW, et al
    Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)31920.
    PubMed     Text format     Abstract available


  59. FINN AV, Virmani R
    Biodegradable polymer drug-eluting stents: non-inferiority waiting for superiority?
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32063.
    PubMed     Text format    


  60. ALI ZA, Maehara A, Genereux P, Shlofmitz RA, et al
    Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)31922.
    PubMed     Text format     Abstract available


  61. SERRUYS PW, Chevalier B, Sotomi Y, Cequier A, et al
    Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32050.
    PubMed     Text format     Abstract available


  62. ROSSIGNOL P, Pitt B, Thompson A, Zannad F, et al
    Roadmap for cardiovascular prevention trials in chronic kidney disease.
    Lancet. 2016;388:1964-1966.
    PubMed     Text format    


  63. GUAN WJ, Zheng XY, Chung KF, Zhong NS, et al
    Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action.
    Lancet. 2016;388:1939-1951.
    PubMed     Text format     Abstract available


  64. ISAAZ K, Gerbay A
    Deferred stenting in acute ST elevation myocardial infarction.
    Lancet. 2016;388:1371.
    PubMed     Text format    


  65. KELBAEK H, Hofsten DE, Engstrom T, Helqvist S, et al
    Deferred stenting in acute ST elevation myocardial infarction - Authors' reply.
    Lancet. 2016;388:1371-1372.
    PubMed     Text format    


  66. WONG EM, Chair SY, Leung DY, Sit JW, et al
    The effect of an e-health web-based support programme on psychological outcomes and health related quality of life among Chinese patients with coronary heart disease: a parallel-group randomised controlled trial.
    Lancet. 2016;388 Suppl 1:S86.
    PubMed     Text format     Abstract available


    September 2016
  67. FEINBERG MW
    No small task: therapeutic targeting of Lp(a) for cardiovascular disease.
    Lancet. 2016 Sep 21. pii: S0140-6736(16)31329.
    PubMed     Text format    


    August 2016
  68. CAYLA G, Cuisset T, Silvain J, Leclercq F, et al
    Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31323.
    PubMed     Text format     Abstract available


  69. VIDAL-PETIOT E, Ford I, Greenlaw N, Ferrari R, et al
    Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31326.
    PubMed     Text format     Abstract available


  70. MANCIA G
    Should blood pressure reduction be aggressive in patients with hypertension and coronary artery disease?
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31398.
    PubMed     Text format    


  71. WEINTRAUB WS
    Invasive management of acute coronary syndromes.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31273.
    PubMed     Text format    


  72. WALLENTIN L, Lindhagen L, Arnstrom E, Husted S, et al
    Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31276.
    PubMed     Text format     Abstract available


  73. REED GW, Rossi JE, Cannon CP
    Acute myocardial infarction.
    Lancet. 2016 Aug 5. pii: S0140-6736(16)30677.
    PubMed     Text format     Abstract available


    July 2016
  74. SNYDER A
    Philip Majerus.
    Lancet. 2016;388:458.
    PubMed     Text format    


  75. KAIN K
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:126.
    PubMed     Text format    


  76. ETTEHAD D, Emdin CA, Kiran A, Rahimi K, et al
    Blood pressure lowering for cardiovascular disease - Authors' reply.
    Lancet. 2016;388:126-7.
    PubMed     Text format    


  77. O'KEEFFE DT, Maraka S
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    PubMed     Text format    


  78. SMULDERS YM, Muller M
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125-6.
    PubMed     Text format    


  79. COLLINS DR, Albasri A, O'Sullivan J, Bobrovitz N, et al
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    PubMed     Text format    


  80. STONE GW, Gao R, Kimura T, Simonton C, et al
    Optimum technique to reduce risk of stent thrombosis - Authors' reply.
    Lancet. 2016;388:127-8.
    PubMed     Text format    


  81. SHAH R
    Optimum technique to reduce risk of stent thrombosis.
    Lancet. 2016;388:127.
    PubMed     Text format    


    June 2016
  82. GLADWIN MT
    Cardiovascular complications and risk of death in sickle-cell disease.
    Lancet. 2016;387:2565-74.
    PubMed     Text format     Abstract available


  83. TEGN N, Abdelnoor M, Aaberge L, Endresen K, et al
    Invasive strategy in acute coronary syndrome - Authors' reply.
    Lancet. 2016;387:2504.
    PubMed     Text format    


  84. MATHEW ST, Pakala AV, Thadani U
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503-4.
    PubMed     Text format    


  85. SHAH R
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503.
    PubMed     Text format    


  86. TIMMIS A
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503.
    PubMed     Text format    


  87. POVSIC TJ, Zeiher AM
    IxCELL-DCM: rejuvenation for cardiac regenerative therapy?
    Lancet. 2016;387:2362-3.
    PubMed     Text format    


  88. FUJITA T
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2289.
    PubMed     Text format    


  89. FORD C, Whitehead SJ, Gama R, Willmer KA, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2289.
    PubMed     Text format    


  90. SHAH AS, Anand A, Chapman AR, Newby DE, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction - Authors' reply.
    Lancet. 2016;387:2289-91.
    PubMed     Text format    


  91. BOEDDINGHAUS J, Twerenbold R, Nestelberger T, Wildi K, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2288.
    PubMed     Text format    


  92. MULLEN L, Chew PG, Frost F, Obafemi T, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2288-9.
    PubMed     Text format    


  93. DALE A, Slade E, Heneghan C
    Outcomes reporting of the FAME trial.
    Lancet. 2016;387:2292.
    PubMed     Text format    


    May 2016
  94. LAFONT A, Mennuni MG
    Effect on death of scaffold thrombosis versus stent thrombosis.
    Lancet. 2016;387:2198.
    PubMed     Text format    


  95. KAUFMAN JD, Adar SD, Barr RG, Budoff M, et al
    Association between air pollution and coronary artery calcification within six metropolitan areas in the USA (the Multi-Ethnic Study of Atherosclerosis and Air Pollution): a longitudinal cohort study.
    Lancet. 2016 May 24. pii: S0140-6736(16)00378.
    PubMed     Text format     Abstract available


  96. MENTE A, O'Donnell M, Rangarajan S, Dagenais G, et al
    Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies.
    Lancet. 2016 May 20. pii: S0140-6736(16)30467.
    PubMed     Text format     Abstract available


  97. SABATE M, Brugaletta S
    Outcomes in the EXAMINATION trial - Authors' reply.
    Lancet. 2016;387:1998.
    PubMed     Text format    


  98. DRYSDALE H, Hartley P, Goldacre B
    Outcomes in the EXAMINATION trial.
    Lancet. 2016;387:1997-8.
    PubMed     Text format    


  99. CASSESE S, Kastrati A
    Risk of stent thrombosis with bioresorbable vascular scaffolds - Authors' reply.
    Lancet. 2016;387:1904.
    PubMed     Text format    


  100. SHAH R, Ramos-Bondy B, Mizeracki A
    Risk of stent thrombosis with bioresorbable vascular scaffolds.
    Lancet. 2016;387:1903.
    PubMed     Text format    


    April 2016
  101. VESTBO J, Anderson JA, Brook RD, Calverley PM, et al
    Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Lancet. 2016;387:1817-1826.
    PubMed     Text format     Abstract available


  102. VAN 'T HOF AW, Ottervanger JP
    Primary angioplasty for STEMI: hard to improve upon.
    Lancet. 2016 Apr 1. pii: S0140-6736(16)30123.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: